AstraZeneca and Daiichi Sankyo are aiming to establish their star antibody-drug conjugate (ADC) Enhertu as a first-line treatment in HER2-positive breast cancer after recording “highly ...

Enhertu plus Perjeta showed significant improvement in progression-free survival in HER2-positive metastatic breast cancer patients compared to standard treatment. The DESTINY-Breast09 trial is the ...

AstraZeneca and Daiichi Sankyo are preparing regulatory filings that could make their HER2-directed antibody-drug conjugate (ADC) Enhertu an option for previously untreated breast cancer for the ...

AstraZeneca (NASDAQ:AZN) said on Monday that the late-stage trial for Enhertu, in combination with pertuzumab, showed significant improvement as a first line treatment of metastatic breast cancer ...

DESTINY-Breast09 Phase III trial of AstraZeneca (AZN) and Daiichi Sankyo’s ENHERTU is the first trial in more than a decade to demonstrate superior efficacy across a broad HER2-positive ...

But the companies said Monday that the planned interim analysis showed the drug, Enhertu, led to a “highly statistically significant and clinically meaningful improvement in progression-free ...

(RTTNews) - Daiichi Sankyo Co., Ltd. (DSKYF.PK) announced Monday that Enhertu (trastuzumab deruxtecan), co-developed and commercialized with British drug major AstraZeneca Plc. (AZN.L, AZN), Plus ...

Topline results from a planned interim analysis of the DESTINY-Breast09 phase 3 trial showed Enhertu in combination with pertuzumab demonstrated a highly statistically significant and clinically ...

Amid these market pressures, the company's collaboration with Daiichi Sankyo was highlighted by the announcement of successful phase 3 trial results for ENHERTU, which positively impacts the ...

resulting in everything from Firaxis’ XCOM games and Tom Clancy’s Ghost Recon Breakpoint to Insurgency: Sandstorm and Arma 3. Now, Microprose is returning with Airborne Ranger: Fightout ...

AstraZeneca and Daiichi Sankyo have claimed their seventh FDA approval for Enhertu, getting the go-ahead for the blockbuster drug as a second-line treatment for patients with HER2-low and HER2 ...